Ricky Turgeon BSc(Pharm), ACPR, PharmD
Assistant Professor
Scientist, Centre for Advancing Health Outcomes
Clinical Pharmacy Specialist, PHARM-HF Clinic, St. Paul’s Hospital
Researcher, Centre for Cardiovascular Innovation
Associate Member, UBC Division of Cardiology
Dr. Ricky Turgeon received his BSc(Pharm) in 2012 from the Dalhousie University College of Pharmacy, his ACPR from the Lower Mainland Pharmacy Services Residency Program in 2013, and his PharmD in the Faculty of Pharmaceutical Sciences at UBC in 2015. He then completed a two-year post-doctoral fellowship in cardiovascular pharmacotherapy at the University of Alberta Division of Cardiology in 2018. Currently, Dr. Turgeon is assistant professor at the UBC Faculty of Pharmaceutical Sciences, and clinical pharmacy specialist at the PHARM-HF clinic, a pharmacist-led heart failure medication optimization clinic, at St. Paul's Hospital in Vancouver.
Dr. Turgeon’s research focuses on integrating evidence and shared decision-making into clinical practice to optimize the care of people living with cardiovascular disease. His clinical focus is in optimal use of heart failure pharmacotherapy, medication safety in cardiovascular disease, and medications to reduce cardiovascular risk (e.g., antithrombotic, lipid-lowering, and antihypertensive medications).
His group uses various methods, including observational designs (cohort or case-control study using administrative data and clinical registries), clinical prediction model development and validation, pragmatic randomized controlled trials, and evidence syntheses (systematic reviews with or without meta-analyses, scoping reviews, and modeling studies) to address important clinical questions in cardiovascular pharmacotherapy.
Bainey K, Marquis-Gravel G, Belley-Côté E, Turgeon RD, et al. 2023 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol 2023[online]. Available at: https://onlinecjc.ca/article/S0828-282X(23)01841-X/fulltext
Beauchesne ABM, Koshman SK, Beavers CJ, Gorman SK, Turgeon RD. Defining pharmacist activities in ambulatory heart failure clinics: North American survey and modified Delphi study. J Am Coll Clin Pharm 2023;6:1180-90. Available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.1855
MacDonald BJ, Turgeon RD. Incorporation of Shared Decision-Making in International Cardiovascular Guidelines, 2012-2022. JAMA Network Open 2023;6:e2332793. doi:10.1001/jamanetworkopen.2023.32793 Available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2809054
MacDonald BJ, Virani SA, Zieroth S, Turgeon RD. Heart Failure Management in 2023: A Pharmacotherapy and Lifestyle Focused Comparison of Current International Guidelines. Can J Cardiol Open 2023;5:629-40. Available at: https://www.cjcopen.ca/article/S2589-790X(23)00123-3/fulltext
Turgeon RD, Koshman SL, Dong Y, Graham MM. P2Y12 inhibitor adherence trajectories in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prognostic implications. Eur Heart J 2022;43:2303-13. Available at: https://doi.org/10.1093/eurheartj/ehac116
Turgeon RD, Althouse AD, Cohen JB, Enache B, Hogenesch JB, Johansen ME, Mehta R, Meyerowitz-Katz G, Ziaeian B, Hiremath S. Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: Controversies in hypertension – con side of the argument. Hypertension 2021;78:871-8.
Turgeon RD, Barry AR, Hawkins NH, Ellis UM. Pharmacotherapy for Heart Failure with Reduced Ejection Fraction and Health-Related Quality of Life: Systematic Review and Meta-Analysis. Eur J Heart Fail 2021;23(4):578-89.
Andrade JG, Wazni OM, Kuniss M, Hawkins NM, Deyell MW, Chierchia GB, Nissen S, Verma A, Wells GA, Turgeon RD. Cryoballoon ablation as initial treatment for atrial fibrillation: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;78:914-30. Available at: https://www.jacc.org/doi/pdf/10.1016/j.jacc.2021.06.038
Wong E, Fordyce CB, Wong G, Lee T, Perry Arnesen M, Mackay M, Singer J, Cairns J, Tocher W, Turgeon RD. Predictors of the use of mineralocorticoid receptor antagonists in patients with left ventricular dysfunction post-ST-segment-elevation myocardial infarction. J Am Heart Assoc 2021;0:e019167. Available online at: https://www.ahajournals.org/doi/full/10.1161/JAHA.120.019167
Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, Graham MM. Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Internal Medicine 2020;80(3):420-8.
"Best Clinical Science Award." Turgeon RD. University of Alberta, Faculty of Medicine and Dentistry – Mazankowski Alberta Heart Institute 2018 Cardiac Sciences Research Day. June 2018.
“Resident Impact Award.” Turgeon RD. Lower Mainland Pharmacy Services Pharmacy Practice Residency Program. June 2013.
“Patient Treatment Preferences and Decisional Needs for Heart Failure Medications” Turgeon RD (PI). $100,000. CIHR Project Grant – Priority Announcement: Patient-Oriented Research (Early-Career Investigator). 2022-2023.
“Pharmacist-led intervention for Optimal Heart Failure Medications: A pilot randomized controlled trial (PHARM Optimal-HF Pilot).” Turgeon RD (PI). $48,587.50. Canadian Foundation for Pharmacy Innovation Fund Grant. 2022-2024.
“Canadian Heart Function Alliance”. CIHR Heart Failure Research Network Team Grant. Co-I. $5,000,000. CIHR Heart Failure Research Network Team Grant. 2022-2027.
“Repository and Development of Point-of-Care Decision Support Tools for Family Physicians.” Korownyk T (PI), Turgeon R, Kolber M, McCOrmack J, Falk J, Ton J. University of Alberta (Northern Alberta Academic Family Medicine Fund). 2022-2023.
“Patient Treatment Preferences and Decisional Needs for Heart Failure Medications” Turgeon RD (PI). $450,000. Michael Smith Health Research BC 2022 Health Professional-Investigator. 2023-2028.
“Heartfelt Innovations: Empowering Communities with Quality Heart Failure Care - Shared Decision-Making in HF & the SHARE-HF Program.” Vascular 2023. Montreal, QC; October 29, 2023.
“CCS/ACC Joint Plenary: Multidisciplinary Heart Failure Team: Meeting Future Demands - The Role of Pharmacists in HF Care Delivery.” Vascular 2023. Montreal, QC; October 28, 2023.
“Update on Heart Failure with Ejection Fraction >40%: What to with the Half of HF Patients Who Don’t Have HFrEF?” Canadian Pharmacy Heart Failure Symposium. Virtual; February 4, 2023.
Centre for Health Evaluation & Outcome Sciences (CHEOS). Discover PHARM-HF, a clinic connecting pharmacists with patients with heart failure. November 24, 2021. Available at: https://cheos.ubc.ca/research-in-action/discover-pharm-hf-a-clinic-connecting-pharmacists-with-patients-with-heart-failure/
Interview. Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists. TCTMD. 2021 July 9. Available at: https://www.tctmd.com/news/studies-explore-post-mi-use-beta-blockers-mineralocorticoid-receptor-antagonists
Interview. Should journals credit eagle-eyed readers by name in retraction notices? Retraction Watch. 2019 February 6. Available at: https://retractionwatch.com/2019/02/06/should-journals-credit-eagle-eyed-readers-in-retraction-notices/
Contact Details
Office 5523, Pharmaceutical Sciences Building